Press releases
STORM Therapeutics today announced the publication of data in the internationally renowned scientific journal Nature linking an essential RNA-modifying enzyme to acute myeloid leukaemia (AML).
Read more
STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, today announced the appointment of Professor Paul Workman to its Board.
Read more
A ceremony at Newmarket Racecourse attracted some of the brightest entrepreneurs in the region.
Read more
STORM Therapeutics is looking to harness the power of RNA epigenetics by honing in on the modulation of RNA-modifying enzymes.
Read more
STORM Therapeutics and Evotec to exploit RNA modulating enzymes for novel epigenetic drug discovery
Read more